Weave Bio raises $20M Series A

Weave Bio raised a $20 million Series A on October 16, 2025 to expand its artificial-intelligence software for drug regulatory submissions. (businesswire.com) The San Francisco company said the round was led by USVP, with participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital. Weave said the financing brought its total capital raised to $36 million. (businesswire.com) Weave sells software for one of biotech’s slowest jobs: assembling the documents, tables, figures, and evidence packages that drug companies send to regulators. Its platform is built around electronic common technical document, or eCTD, templates used in formal submissions. (weave.bio 1) (weave.bio 2) On its website, Weave says the product handles data organization, authoring, review, publishing, and responses to health-authority questions in one system. The company says teams can trace drafted content back to source material and update linked sections when data changes. (weave.bio 1) (weave.bio 2) The new money is earmarked for broader product coverage across the regulatory lifecycle, including new drug application and biologics license application filings, health-authority question responses, and post-market updates. Weave also said it plans to expand beyond the U.S. Food and Drug Administration into Europe, Japan, and Latin America. (businesswire.com) Chief executive Brandon Rice told BiotechTV in October 2025 that in one pharma project, Weave drafted documents in three hours that would have taken humans about 100 hours. That claim came days after the funding announcement. (biotechtv.com) The company has been building around that pitch since at least 2023, when it described itself as an AI-native regulatory automation platform for novel therapeutic candidates. A company podcast page says its AutoIND product had already been adopted for preclinical investigational new drug submissions. (weave.bio) Weave’s financing also followed a September 30, 2025 partnership with Parexel, the large clinical research organization, to use Weave’s platform in regulatory submission work. Parexel said the collaboration was aimed at speeding submission processes and time to market for new therapies. (markets.financialcontent.com) By March 2026, Weave had added an advisory board with regulatory leaders from Takeda, Boehringer Ingelheim, Gilead, Stanford, and Serrado Capital. The company framed that move as part of a push to align its software with the scientific and policy demands of modern drug development. (pharmiweb.com) The bet behind the Series A is simple: if biotech companies can cut weeks of manual drafting and review from filings, they can move programs faster without changing the science. Weave is now spending against that idea in a market where regulators still require the paperwork to be exact. (businesswire.com) (weave.bio)